104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026
SB3223

 

Introduced 2/2/2026, by Sen. Doris Turner

 

SYNOPSIS AS INTRODUCED:
 
225 ILCS 85/3

    Amends the Pharmacy Practice Act. Provides that "practice of pharmacy" includes the monitoring of medication recalls, including notifying patients of applicable medication recalls at the point of sale.


LRB104 18559 AAS 32002 b

 

 

A BILL FOR

 

SB3223LRB104 18559 AAS 32002 b

1    AN ACT concerning regulation.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Pharmacy Practice Act is amended by
5changing Section 3 as follows:
 
6    (225 ILCS 85/3)
7    (Section scheduled to be repealed on January 1, 2028)
8    Sec. 3. Definitions. For the purpose of this Act, except
9where otherwise limited therein:
10    (a) "Pharmacy" or "drugstore" means and includes every
11store, shop, pharmacy department, or other place where
12pharmacist care is provided by a pharmacist (1) where drugs,
13medicines, or poisons are dispensed, sold or offered for sale
14at retail, or displayed for sale at retail; or (2) where
15prescriptions of physicians, dentists, advanced practice
16registered nurses, physician assistants, veterinarians,
17podiatric physicians, or optometrists, within the limits of
18their licenses, are compounded, filled, or dispensed; or (3)
19which has upon it or displayed within it, or affixed to or used
20in connection with it, a sign bearing the word or words
21"Pharmacist", "Druggist", "Pharmacy", "Pharmaceutical Care",
22"Apothecary", "Drugstore", "Medicine Store", "Prescriptions",
23"Drugs", "Dispensary", "Medicines", or any word or words of

 

 

SB3223- 2 -LRB104 18559 AAS 32002 b

1similar or like import, either in the English language or any
2other language; or (4) where the characteristic prescription
3sign (Rx) or a similar design is exhibited; or (5) any store,
4or shop, or other place with respect to which any of the above
5words, objects, signs, or designs are used in any
6advertisement.
7    (b) "Drugs" means and includes (1) articles recognized in
8the official United States Pharmacopoeia/National Formulary
9(USP/NF), or any supplement thereto and being intended for and
10having for their main use the diagnosis, cure, mitigation,
11treatment, or prevention of disease in man or other animals,
12as approved by the United States Food and Drug Administration,
13but does not include devices or their components, parts, or
14accessories; and (2) all other articles intended for and
15having for their main use the diagnosis, cure, mitigation,
16treatment, or prevention of disease in man or other animals,
17as approved by the United States Food and Drug Administration,
18but does not include devices or their components, parts, or
19accessories; and (3) articles (other than food) having for
20their main use and intended to affect the structure or any
21function of the body of man or other animals; and (4) articles
22having for their main use and intended for use as a component
23or any articles specified in clause (1), (2), or (3); but does
24not include devices or their components, parts, or
25accessories.
26    (c) "Medicines" means and includes all drugs intended for

 

 

SB3223- 3 -LRB104 18559 AAS 32002 b

1human or veterinary use approved by the United States Food and
2Drug Administration.
3    (d) "Practice of pharmacy" means:
4        (1) the interpretation and the provision of assistance
5    in the monitoring, evaluation, and implementation of
6    prescription drug orders;
7        (2) the dispensing of prescription drug orders;
8        (3) participation in drug and device selection;
9        (4) drug administration limited to the administration
10    of oral, topical, injectable, intranasal, and inhalation
11    as follows:
12            (A) in the context of patient education on the
13        proper use or delivery of medications;
14            (B) vaccination of patients 3 years of age and
15        older pursuant to a valid prescription or standing
16        order, by a physician licensed to practice medicine in
17        all its branches, upon completion of appropriate
18        training, including how to address contraindications
19        and adverse reactions set forth by rule, with
20        notification to the patient's primary care provider
21        and appropriate record retention, or pursuant to
22        hospital pharmacy and therapeutics committee policies
23        and procedures. Eligible vaccines are those listed on
24        the U.S. Centers for Disease Control and Prevention
25        (CDC) Recommended Immunization Schedule, the CDC's
26        Health Information for International Travel, the U.S.

 

 

SB3223- 4 -LRB104 18559 AAS 32002 b

1        Food and Drug Administration's Vaccines Licensed and
2        Authorized for Use in the United States, or the State
3        Guidelines for Communicable Disease Prevention issued
4        by the Director of Public Health pursuant to Section
5        1.2 of the Communicable Disease Prevention Act, except
6        that a pharmacist shall not administer to patients
7        below the age of 7 any vaccine required to be
8        administered under 77 Ill. Adm. Code 665. All vaccines
9        administered in accordance with this subsection shall
10        be reported to the Department of Public Health's
11        Immunization Information System. As applicable to the
12        State's Medicaid program and other payers, vaccines
13        ordered and administered in accordance with this
14        subsection shall be covered and reimbursed at no less
15        than the rate that the vaccine is reimbursed when
16        ordered and administered by a physician;
17            (B-5) (blank);
18            (C) administration of injections of
19        alpha-hydroxyprogesterone caproate, pursuant to a
20        valid prescription, by a physician licensed to
21        practice medicine in all its branches, upon completion
22        of appropriate training, including how to address
23        contraindications and adverse reactions set forth by
24        rule, with notification to the patient's physician and
25        appropriate record retention, or pursuant to hospital
26        pharmacy and therapeutics committee policies and

 

 

SB3223- 5 -LRB104 18559 AAS 32002 b

1        procedures; and
2            (D) administration of long-acting injectables for
3        mental health or substance use disorders pursuant to a
4        valid prescription by the patient's physician licensed
5        to practice medicine in all its branches, advanced
6        practice registered nurse, or physician assistant upon
7        completion of appropriate training conducted by an
8        Accreditation Council of Pharmaceutical Education
9        accredited provider, including how to address
10        contraindications and adverse reactions set forth by
11        rule, with notification to the patient's physician and
12        appropriate record retention, or pursuant to hospital
13        pharmacy and therapeutics committee policies and
14        procedures;
15        (5) (blank);
16        (5.5) the monitoring of medication recalls, including
17    notifying patients of applicable medication recalls at the
18    point of sale;
19        (6) drug regimen review;
20        (7) drug or drug-related research;
21        (8) the provision of patient counseling;
22        (9) the practice of telepharmacy;
23        (10) the provision of those acts or services necessary
24    to provide pharmacist care;
25        (11) medication therapy management;
26        (12) the responsibility for compounding and labeling

 

 

SB3223- 6 -LRB104 18559 AAS 32002 b

1    of drugs and devices (except labeling by a manufacturer,
2    repackager, or distributor of non-prescription drugs and
3    commercially packaged legend drugs and devices), proper
4    and safe storage of drugs and devices, and maintenance of
5    required records;
6        (13) the assessment and consultation of patients and
7    dispensing of contraceptives, including emergency
8    contraception;
9        (14) the initiation, dispensing, or administration of
10    drugs, laboratory tests, assessments, referrals, and
11    consultations for human immunodeficiency virus
12    pre-exposure prophylaxis and human immunodeficiency virus
13    post-exposure prophylaxis under Section 43.5;
14        (15) without a valid prescription or standing order,
15    vaccination of patients 3 years of age and older for
16    COVID-19 or influenza intramuscularly or intranasally
17    pursuant to the following conditions:
18            (A) the vaccine must be authorized or licensed by
19        the United States Food and Drug Administration;
20            (B) the vaccine must be ordered and administered
21        according to the recommendations of the Advisory
22        Committee on Immunization Practices as adopted by the
23        United States Centers for Disease Control and
24        Prevention or the State Guidelines for Communicable
25        Disease Prevention issued by the Director of Public
26        Health pursuant to Section 1.2 of the Communicable

 

 

SB3223- 7 -LRB104 18559 AAS 32002 b

1        Disease Prevention Act;
2            (C) the pharmacist must complete a course of
3        training accredited by the Accreditation Council on
4        Pharmacy Education or a similar health authority or
5        professional body approved by the Division of
6        Professional Regulation;
7            (D) the pharmacist must have a current certificate
8        in basic cardiopulmonary resuscitation;
9            (E) the pharmacist must complete, during each
10        State licensing period, a minimum of 2 hours of
11        immunization-related continuing pharmacy education
12        approved by the Accreditation Council on Pharmacy
13        Education;
14            (F) the pharmacist must report all vaccines
15        administered to the Department of Public Health
16        Immunization Information System in addition to
17        complying with recordkeeping and reporting
18        requirements of the jurisdiction in which the
19        pharmacist administers vaccines, including informing
20        the patient's primary care primary-care provider, when
21        available, and complying with requirements whereby the
22        person administering a vaccine must review the vaccine
23        registry or other vaccination records prior to
24        administering the vaccine; and
25            (G) the pharmacist must inform the pharmacist's
26        patients who are less than 18 years old, as well as the

 

 

SB3223- 8 -LRB104 18559 AAS 32002 b

1        adult caregiver accompanying the child, of the
2        importance of a well-child visit with a pediatrician
3        or other licensed primary care primary-care provider
4        and must refer patients as appropriate;
5        (16) the ordering and administration of COVID-19
6    therapeutics subcutaneously, intramuscularly, or orally
7    with notification to the patient's physician and
8    appropriate record retention or pursuant to hospital
9    pharmacy and therapeutics committee policies and
10    procedures. Eligible therapeutics are those approved,
11    authorized, or licensed by the United States Food and Drug
12    Administration and must be administered subcutaneously,
13    intramuscularly, or orally in accordance with that
14    approval, authorization, or licensing; and
15        (17) the ordering and administration of point of care
16    tests, screenings, and treatments for (i) influenza, (ii)
17    SARS-CoV-2, (iii) Group A Streptococcus, (iv) respiratory
18    syncytial virus, (v) adult-stage head louse, and (vi)
19    health conditions identified by a statewide public health
20    emergency, as defined in the Illinois Emergency Management
21    Agency Act, with notification to the patient's physician,
22    if any, and appropriate record retention or pursuant to
23    hospital pharmacy and therapeutics committee policies and
24    procedures. Eligible tests and screenings are those
25    approved, authorized, or licensed by the United States
26    Food and Drug Administration and must be administered in

 

 

SB3223- 9 -LRB104 18559 AAS 32002 b

1    accordance with that approval, authorization, or
2    licensing.
3        A pharmacist who orders or administers tests or
4    screenings for health conditions described in this
5    paragraph may use a test that may guide clinical
6    decision-making for the health condition that is waived
7    under the federal Clinical Laboratory Improvement
8    Amendments of 1988 and regulations promulgated thereunder
9    or any established screening procedure that is established
10    under a statewide protocol.
11        A pharmacist may delegate the administrative and
12    technical tasks of performing a test for the health
13    conditions described in this paragraph to a registered
14    pharmacy technician or student pharmacist acting under the
15    supervision of the pharmacist.
16        The testing, screening, and treatment ordered under
17    this paragraph by a pharmacist shall not be denied
18    reimbursement under health benefit plans that are within
19    the scope of the pharmacist's license and shall be covered
20    as if the services or procedures were performed by a
21    physician, an advanced practice registered nurse, or a
22    physician assistant.
23        A pharmacy benefit manager, health carrier, health
24    benefit plan, or third-party payor shall not discriminate
25    against a pharmacy or a pharmacist with respect to
26    participation referral, reimbursement of a covered

 

 

SB3223- 10 -LRB104 18559 AAS 32002 b

1    service, or indemnification if a pharmacist is acting
2    within the scope of the pharmacist's license and the
3    pharmacy is operating in compliance with all applicable
4    laws and rules.
5    A pharmacist who performs any of the acts defined as the
6practice of pharmacy in this State must be actively licensed
7as a pharmacist under this Act.
8    (e) "Prescription" means and includes any written, oral,
9facsimile, or electronically transmitted order for drugs or
10medical devices, issued by a physician licensed to practice
11medicine in all its branches, dentist, veterinarian, podiatric
12physician, or optometrist, within the limits of his or her
13license, by a physician assistant in accordance with
14subsection (f) of Section 4, or by an advanced practice
15registered nurse in accordance with subsection (g) of Section
164, containing the following: (1) name of the patient; (2) date
17when prescription was issued; (3) name and strength of drug or
18description of the medical device prescribed; and (4)
19quantity; (5) directions for use; (6) prescriber's name,
20address, and signature; and (7) DEA registration number where
21required, for controlled substances. The prescription may, but
22is not required to, list the illness, disease, or condition
23for which the drug or device is being prescribed. DEA
24registration numbers shall not be required on inpatient drug
25orders. A prescription for medication other than controlled
26substances shall be valid for up to 15 months from the date

 

 

SB3223- 11 -LRB104 18559 AAS 32002 b

1issued for the purpose of refills, unless the prescription
2states otherwise.
3    (f) "Person" means and includes a natural person,
4partnership, association, corporation, government entity, or
5any other legal entity.
6    (g) "Department" means the Department of Financial and
7Professional Regulation.
8    (h) "Board of Pharmacy" or "Board" means the State Board
9of Pharmacy of the Department of Financial and Professional
10Regulation.
11    (i) "Secretary" means the Secretary of Financial and
12Professional Regulation.
13    (j) "Drug product selection" means the interchange for a
14prescribed pharmaceutical product in accordance with Section
1525 of this Act and Section 3.14 of the Illinois Food, Drug and
16Cosmetic Act.
17    (k) "Inpatient drug order" means an order issued by an
18authorized prescriber for a resident or patient of a facility
19licensed under the Nursing Home Care Act, the ID/DD Community
20Care Act, the MC/DD Act, the Specialized Mental Health
21Rehabilitation Act of 2013, the Hospital Licensing Act, or the
22University of Illinois Hospital Act, or a facility which is
23operated by the Department of Human Services (as successor to
24the Department of Mental Health and Developmental
25Disabilities) or the Department of Corrections.
26    (k-5) "Pharmacist" means an individual health care

 

 

SB3223- 12 -LRB104 18559 AAS 32002 b

1professional and provider currently licensed by this State to
2engage in the practice of pharmacy.
3    (l) "Pharmacist in charge" means the licensed pharmacist
4whose name appears on a pharmacy license and who is
5responsible for all aspects of the operation related to the
6practice of pharmacy.
7    (m) "Dispense" or "dispensing" means the interpretation,
8evaluation, and implementation of a prescription drug order,
9including the preparation and delivery of a drug or device to a
10patient or patient's agent in a suitable container
11appropriately labeled for subsequent administration to or use
12by a patient in accordance with applicable State and federal
13laws and regulations. "Dispense" or "dispensing" does not mean
14the physical delivery to a patient or a patient's
15representative in a home or institution by a designee of a
16pharmacist or by common carrier. "Dispense" or "dispensing"
17also does not mean the physical delivery of a drug or medical
18device to a patient or patient's representative by a
19pharmacist's designee within a pharmacy or drugstore while the
20pharmacist is on duty and the pharmacy is open.
21    (n) "Nonresident pharmacy" means a pharmacy that is
22located in a state, commonwealth, or territory of the United
23States, other than Illinois, that delivers, dispenses, or
24distributes, through the United States Postal Service, a
25commercially acceptable parcel delivery service, or other
26common carrier, to Illinois residents, any substance which

 

 

SB3223- 13 -LRB104 18559 AAS 32002 b

1requires a prescription.
2    (o) "Compounding" means the preparation and mixing of
3components, excluding flavorings, (1) as the result of a
4prescriber's prescription drug order or initiative based on
5the prescriber-patient-pharmacist relationship in the course
6of professional practice or (2) for the purpose of, or
7incident to, research, teaching, or chemical analysis and not
8for sale or dispensing. "Compounding" includes the preparation
9of drugs or devices in anticipation of receiving prescription
10drug orders based on routine, regularly observed dispensing
11patterns. Commercially available products may be compounded
12for dispensing to individual patients only if all of the
13following conditions are met: (i) the commercial product is
14not reasonably available from normal distribution channels in
15a timely manner to meet the patient's needs and (ii) the
16prescribing practitioner has requested that the drug be
17compounded.
18    (p) (Blank).
19    (q) (Blank).
20    (r) "Patient counseling" means the communication between a
21pharmacist or a student pharmacist under the supervision of a
22pharmacist and a patient or the patient's representative about
23the patient's medication or device for the purpose of
24optimizing proper use of prescription medications or devices.
25"Patient counseling" may include without limitation (1)
26obtaining a medication history; (2) acquiring a patient's

 

 

SB3223- 14 -LRB104 18559 AAS 32002 b

1allergies and health conditions; (3) facilitation of the
2patient's understanding of the intended use of the medication;
3(4) proper directions for use; (5) significant potential
4adverse events; (6) potential food-drug interactions; and (7)
5the need to be compliant with the medication therapy. A
6pharmacy technician may only participate in the following
7aspects of patient counseling under the supervision of a
8pharmacist: (1) obtaining medication history; (2) providing
9the offer for counseling by a pharmacist or student
10pharmacist; and (3) acquiring a patient's allergies and health
11conditions.
12    (s) "Patient profiles" or "patient drug therapy record"
13means the obtaining, recording, and maintenance of patient
14prescription information, including prescriptions for
15controlled substances, and personal information.
16    (t) (Blank).
17    (u) "Medical device" or "device" means an instrument,
18apparatus, implement, machine, contrivance, implant, in vitro
19reagent, or other similar or related article, including any
20component part or accessory, required under federal law to
21bear the label "Caution: Federal law requires dispensing by or
22on the order of a physician". A seller of goods and services
23who, only for the purpose of retail sales, compounds, sells,
24rents, or leases medical devices shall not, by reasons
25thereof, be required to be a licensed pharmacy.
26    (v) "Unique identifier" means an electronic signature,

 

 

SB3223- 15 -LRB104 18559 AAS 32002 b

1handwritten signature or initials, thumbprint, or other
2acceptable biometric or electronic identification process as
3approved by the Department.
4    (w) "Current usual and customary retail price" means the
5price that a pharmacy charges to a non-third-party payor.
6    (x) "Automated pharmacy system" means a mechanical system
7located within the confines of the pharmacy or remote location
8that performs operations or activities, other than compounding
9or administration, relative to the storage, packaging,
10dispensing, or distribution of medication, and which collects,
11controls, and maintains all transaction information.
12    (y) "Drug regimen review" means and includes the
13evaluation of prescription drug orders and patient records for
14(1) known allergies; (2) drug or potential therapy
15contraindications; (3) reasonable dose, duration of use, and
16route of administration, taking into consideration factors
17such as age, gender, and contraindications; (4) reasonable
18directions for use; (5) potential or actual adverse drug
19reactions; (6) drug-drug interactions; (7) drug-food
20interactions; (8) drug-disease contraindications; (9)
21therapeutic duplication; (10) patient laboratory values when
22authorized and available; (11) proper utilization (including
23over or under utilization) and optimum therapeutic outcomes;
24and (12) abuse and misuse.
25    (z) "Electronically transmitted prescription" means a
26prescription that is created, recorded, or stored by

 

 

SB3223- 16 -LRB104 18559 AAS 32002 b

1electronic means; issued and validated with an electronic
2signature; and transmitted by electronic means directly from
3the prescriber to a pharmacy. An electronic prescription is
4not an image of a physical prescription that is transferred by
5electronic means from computer to computer, facsimile to
6facsimile, or facsimile to computer.
7    (aa) "Medication therapy management services" means a
8distinct service or group of services offered by licensed
9pharmacists, physicians licensed to practice medicine in all
10its branches, advanced practice registered nurses authorized
11in a written agreement with a physician licensed to practice
12medicine in all its branches, or physician assistants
13authorized in guidelines by a supervising physician that
14optimize therapeutic outcomes for individual patients through
15improved medication use. In a retail or other non-hospital
16pharmacy, medication therapy management services shall consist
17of the evaluation of prescription drug orders and patient
18medication records to resolve conflicts with the following:
19        (1) known allergies;
20        (2) drug or potential therapy contraindications;
21        (3) reasonable dose, duration of use, and route of
22    administration, taking into consideration factors such as
23    age, gender, and contraindications;
24        (4) reasonable directions for use;
25        (5) potential or actual adverse drug reactions;
26        (6) drug-drug interactions;

 

 

SB3223- 17 -LRB104 18559 AAS 32002 b

1        (7) drug-food interactions;
2        (8) drug-disease contraindications;
3        (9) identification of therapeutic duplication;
4        (10) patient laboratory values when authorized and
5    available;
6        (11) proper utilization (including over or under
7    utilization) and optimum therapeutic outcomes; and
8        (12) drug abuse and misuse.
9    "Medication therapy management services" includes the
10following:
11        (1) documenting the services delivered and
12    communicating the information provided to patients'
13    prescribers within an appropriate time frame, not to
14    exceed 48 hours;
15        (2) providing patient counseling designed to enhance a
16    patient's understanding and the appropriate use of his or
17    her medications; and
18        (3) providing information, support services, and
19    resources designed to enhance a patient's adherence with
20    his or her prescribed therapeutic regimens.
21    "Medication therapy management services" may also include
22patient care functions authorized by a physician licensed to
23practice medicine in all its branches for his or her
24identified patient or groups of patients under specified
25conditions or limitations in a standing order from the
26physician.

 

 

SB3223- 18 -LRB104 18559 AAS 32002 b

1    "Medication therapy management services" in a licensed
2hospital may also include the following:
3        (1) reviewing assessments of the patient's health
4    status; and
5        (2) following protocols of a hospital pharmacy and
6    therapeutics committee with respect to the fulfillment of
7    medication orders.
8    (bb) "Pharmacist care" means the provision by a pharmacist
9of medication therapy management services, with or without the
10dispensing of drugs or devices, intended to achieve outcomes
11that improve patient health, quality of life, and comfort and
12enhance patient safety.
13    (cc) "Protected health information" means individually
14identifiable health information that, except as otherwise
15provided, is:
16        (1) transmitted by electronic media;
17        (2) maintained in any medium set forth in the
18    definition of "electronic media" in the federal Health
19    Insurance Portability and Accountability Act; or
20        (3) transmitted or maintained in any other form or
21    medium.
22    "Protected health information" does not include
23individually identifiable health information found in:
24        (1) education records covered by the federal Family
25    Educational Right and Privacy Act; or
26        (2) employment records held by a licensee in the

 

 

SB3223- 19 -LRB104 18559 AAS 32002 b

1    licensee's its role as an employer.
2    (dd) "Standing order" means a specific order for a patient
3or group of patients issued by a physician licensed to
4practice medicine in all its branches in Illinois.
5    (ee) "Address of record" means the designated address
6recorded by the Department in the applicant's application file
7or licensee's license file maintained by the Department's
8licensure maintenance unit.
9    (ff) "Home pharmacy" means the location of a pharmacy's
10primary operations.
11    (gg) "Email address of record" means the designated email
12address recorded by the Department in the applicant's
13application file or the licensee's license file, as maintained
14by the Department's licensure maintenance unit.
15(Source: P.A. 103-1, eff. 4-27-23; 103-593, eff. 6-7-24;
16103-612, eff. 1-1-25; 104-312, eff. 1-1-26; 104-417, eff.
178-15-25; 104-439, eff. 12-2-25; revised 12-9-25.)